Japan Myocardial Infarction Market to Reach $310.9 Billion by 2035

Japan myocardial infarction market was valued at $159.2 million in 2025 and is projected to reach $310.9 million by 2035, growing at a CAGR of 7.0% from 2026 to 2035. Market growth is driven by the rising burden of cardiovascular diseases and increasing demand for minimally invasive interventional procedures. According to the World Health Organization, cardiovascular diseases account for nearly 32% of global casualties, highlighting the growing need for effective diagnosis and treatment solutions. In Japan, the aging population and high prevalence of hypertension and lifestyle-related diseases are significantly increasing hospital admissions for acute myocardial infarction, thereby accelerating the adoption of advanced devices such as catheters, pacemakers, and implantable cardioverter defibrillators across hospitals and specialty centres.

Browse the full report description of “Japan Myocardial Infarction Market Size, Share & Trends Analysis Report by Treatment Type (Pharmacological Treatment, Interventional Procedures, Adjunct & Supportive Care), by Medical Device Type (Left Ventricular Assist Device, Pacemaker, Catheters, Implantable Cardioverter Defibrillator, Others), by End-Use Industry (Hospitals, Specialty Centres, ASCs), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/japan-myocardial-infarction-market

Innovation Leaders Transforming the Myocardial Infarction Market

The key players in the Japan myocardial infarction market include top companies such as Johnson & Johnson, Abbott, Medtronic, Siemens Healthineers, and GE HealthCare, among others. The market is witnessing steady growth due to the increasing adoption of interventional cardiology procedures and advanced cardiac monitoring technologies. Hospitals remain the primary end-users, supported by the expansion of catheterization laboratories and improved access to emergency cardiac care across Japan.

• In March 2026, Medtronic announced results from its ALERT trial showing that AI-enabled clinician alerts improved the timely evaluation and treatment of cardiovascular patients. The study demonstrated a 40% increase in valve interventions and enhanced clinical decision-making through EHR-integrated alerts. This advancement highlights the growing role of AI-driven tools in improving interventional outcomes and supporting broader cardiovascular care pathways, including myocardial infarction management.

• In October 2025, Terumo Corporation announced that its OPUSWAVE dual sensor imaging system and DualView catheter received FDA 510(k) clearance, enhancing intravascular imaging capabilities. The system integrates OFDI and IVUS technologies into a single catheter, enabling improved visualization of coronary artery disease during PCI procedures. This innovation supports more precise and efficient interventional treatment of myocardial infarction, strengthening Terumo’s position in the cardiovascular device market.

Market Coverage

• The market number available for – 2025–2035 s
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Treatment Type
• By Medical Device Type
• By End User
• Competitive Landscape: Johnson & Johnson, Abbott, Medtronic, Siemens Healthineers, GE HealthCare, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Japan Myocardial Infarction Market Report Segment

By Treatment Type

• Pharmacological Treatment
• Interventional Procedures
• Adjunct & Supportive Care

By Medical Device Type

• Left Ventricular Assist Device
• Pacemaker
• Catheters
• Implantable Cardioverter Defibrillator
• Others

By End User

• Hospitals
• Specialty Centres
• ASCs

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/japan-myocardial-infarction-market